Cargando…

Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?

Lineage switch between myeloid and lymphoid in acute leukemia is well established as a mechanism for leukemic cells to escape chemotherapy. Cross-lineage transformation is also recognized in some solid tumors on targeted therapy, such as adenocarcinomas of the lung and prostate that transforms to ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hui, Shen, Qi, Chang, Chung-Che, Hu, Shimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733465/
https://www.ncbi.nlm.nih.gov/pubmed/35004320
http://dx.doi.org/10.3389/fonc.2021.795330
_version_ 1784627808852508672
author Liu, Hui
Shen, Qi
Chang, Chung-Che
Hu, Shimin
author_facet Liu, Hui
Shen, Qi
Chang, Chung-Che
Hu, Shimin
author_sort Liu, Hui
collection PubMed
description Lineage switch between myeloid and lymphoid in acute leukemia is well established as a mechanism for leukemic cells to escape chemotherapy. Cross-lineage transformation is also recognized in some solid tumors on targeted therapy, such as adenocarcinomas of the lung and prostate that transforms to neuroendocrine carcinoma on targeted therapy. Now lineage plasticity is increasingly recognized in mature lymphomas, such as small B-cell lymphomas transforming to histiocytic/dendritic cell sarcoma. However, there is no report of aggressive mature B-cell lymphoma switching from one histologic category to another upon targeted therapy. We report here a case of high-grade B-cell lymphoma with MYC and BCL6 rearrangements relapsing as a high-grade plasmablastic neoplasm with MYC and BCL6 rearrangements after R-CHOP and R-EPOCH therapy. Being aware of this rare scenario will help improve our understanding of the underlying mechanisms of therapeutic resistance and progression of lymphoma.
format Online
Article
Text
id pubmed-8733465
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87334652022-01-07 Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma? Liu, Hui Shen, Qi Chang, Chung-Che Hu, Shimin Front Oncol Oncology Lineage switch between myeloid and lymphoid in acute leukemia is well established as a mechanism for leukemic cells to escape chemotherapy. Cross-lineage transformation is also recognized in some solid tumors on targeted therapy, such as adenocarcinomas of the lung and prostate that transforms to neuroendocrine carcinoma on targeted therapy. Now lineage plasticity is increasingly recognized in mature lymphomas, such as small B-cell lymphomas transforming to histiocytic/dendritic cell sarcoma. However, there is no report of aggressive mature B-cell lymphoma switching from one histologic category to another upon targeted therapy. We report here a case of high-grade B-cell lymphoma with MYC and BCL6 rearrangements relapsing as a high-grade plasmablastic neoplasm with MYC and BCL6 rearrangements after R-CHOP and R-EPOCH therapy. Being aware of this rare scenario will help improve our understanding of the underlying mechanisms of therapeutic resistance and progression of lymphoma. Frontiers Media S.A. 2021-12-23 /pmc/articles/PMC8733465/ /pubmed/35004320 http://dx.doi.org/10.3389/fonc.2021.795330 Text en Copyright © 2021 Liu, Shen, Chang and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Hui
Shen, Qi
Chang, Chung-Che
Hu, Shimin
Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
title Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
title_full Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
title_fullStr Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
title_full_unstemmed Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
title_short Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?
title_sort case report: phenotypic switch in high-grade b-cell lymphoma with myc and bcl6 rearrangements: a potential mechanism of therapeutic resistance in lymphoma?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733465/
https://www.ncbi.nlm.nih.gov/pubmed/35004320
http://dx.doi.org/10.3389/fonc.2021.795330
work_keys_str_mv AT liuhui casereportphenotypicswitchinhighgradebcelllymphomawithmycandbcl6rearrangementsapotentialmechanismoftherapeuticresistanceinlymphoma
AT shenqi casereportphenotypicswitchinhighgradebcelllymphomawithmycandbcl6rearrangementsapotentialmechanismoftherapeuticresistanceinlymphoma
AT changchungche casereportphenotypicswitchinhighgradebcelllymphomawithmycandbcl6rearrangementsapotentialmechanismoftherapeuticresistanceinlymphoma
AT hushimin casereportphenotypicswitchinhighgradebcelllymphomawithmycandbcl6rearrangementsapotentialmechanismoftherapeuticresistanceinlymphoma